TY - THES A1 - Kitzenmaier, Alexandra T1 - GlyT2-Mutationen als zweithäufigste Ursache bei Hyperekplexie – Pathologischer Mechanismus der Mutation P429L T1 - GlyT2 mutations as second major cause of hyperekplexia – Pathogenic mechanism of the mutation P429L N2 - Mutationen im Glycintransporter 2 (GlyT2) stellen die präsynaptische Komponente der neurologischen Erkrankung Hyperekplexie oder Startle Disease dar. Der neuronale Na+/Cl- -abhängige GlyT2 ist für das Recycling von Glycin verantwortlich und bildet an inhibitorischen glycinergen Synapsen die Hauptquelle des freigesetzten Transmitters. Dominante, rezessive und zusammengesetzte heterozygote Mutationen wurden bereits identifiziert, von denen die meisten zu einer beeinträchtigten Glycinaufnahme führen. In dieser Arbeit konnten wir eine neue pathogene Mutation innerhalb des neuronalen Glycintransporter-2-Gens (SLC6A5, OMIM604159) in einer Familie identifizieren, in der beide Elternteile heterozygote Träger waren. Ein homozygotes Kind litt an schweren neuromotorischen Defiziten, wohingegen Heterozygote keine Symptome aufwiesen. Die neue rezessive Mutation c.1286C>T erzeugte einen missense Aminosäureaustausch von Prolin gegen Leucin an Position 429 (pP429L) in der Transmembrandomäne 5. Wir haben die GlyT2P429L-Variante mittels Homologiemodellierung, immuncytochemischer Färbungen, Western Blot Analysen, Biotinylierung und funktioneller Glycinaufnahmetests charakterisiert. Der mutierte GlyT2 zeigte beim Proteintransport durch verschiedene intrazelluläre Kompartimente zur Zelloberfläche keine Defizite. Die gesamte Proteinexpression war jedoch signifikant verringert. Obwohl GlyT2P429L an der Zelloberfläche vorhanden ist, zeigte er einen Verlust der Proteinfunktion. Die Co-Expression der Mutante mit dem Wildtyp-Protein, die die Situation der Eltern widerspiegelte, hatte keinen Einfluss auf die Transporterfunktion und erklärte somit ihren nicht symptomatischen Phänotyp. Wenn jedoch die Mutante im Vergleich zum Wildtyp-Protein im Überschuss exprimiert wurde, war die Glycinaufnahme signifikant verringert. Die Strukturanalyse ergab, dass der eingeführte Leucinrest an Position 429 zu Konformationsänderungen in der α-Helix 5 führt, die in unmittelbarer Nähe zur Natriumbindungsstelle des Transporters lokalisiert sind. Dies deutet darauf hin, dass die Zugangsmechanismen des GlyT2 gestört sein könnten und einen vollständigen Verlust der Transportaktivität verursachen. Unsere Ergebnisse belegen, dass P429 in GlyT2 ein strukturell wichtiger Aminosäurerest ist, der eine wichtige funktionelle Rolle beim Glycintransport spielt. N2 - Glycine transporter 2 (GlyT2) mutations represent the presynaptic component of the neurological disease hyperekplexia or startle disease. The neuronal Na+/Cl- -dependent GlyT2 is responsible for glycine recycling and establishes the main source of releasable transmitter at inhibitory glycinergic synapses. In humans, dominant, recessive and compound heterozygous mutations have been identified, most of them leading to impaired glycine uptake. In this study, we identified a novel pathogenic mutation within the neuronal GlyT2 gene (SLC6A5, OMIM604159) in a family with both parents being heterozygous carriers. A homozygous child suffered from severe neuromotor deficits, whereas heterozygous individuals did not reveal any symptoms. The novel recessive mutation c.1286C>T generated a missense amino acid exchange of proline to leucine at position 429 (pP429L) in transmembrane domain 5 of the protein. We characterized the GlyT2P429L variant using homology modeling, immunocytochemical stainings, Western blot analysis, biotinylation, and functional glycine uptake assays. The mutated GlyT2 revealed no deficits in protein trafficking through various intracellular compartments to cellular surface. However, the whole cell protein expression was significantly decreased. Although present at cellular surface, GlyT2P429L showed a loss of protein function. Co-expression of the mutant with the wild-type protein, reflecting the situation in the parents, did not affect transporter function, thus explaining their non-symptomatic phenotype. Nevertheless, when the mutant was expressed in excess compared with the wild-type protein, glycine uptake was significantly reduced. Structural analysis revealed that the introduced leucine residue at position 429 leads to conformational changes in α-helix 5 which is localized in close proximity to the sodium-binding site of the transporter. The data suggest that the gating mechanism of GlyT2 might be disturbed and causes a complete loss of transport activity. Thus, our results support P429 in GlyT2 as structurally important residue displaying a key functional role in glycine transport. KW - Glycin KW - Proteintransport KW - Inhibitorische Synapse KW - Bewegungsstörung KW - Präsynaptische Hyperekplexie KW - Glycintransporter 2 (GlyT2) KW - SLC6A5 KW - Funktionsverlust KW - Konformationsänderung KW - startle disease KW - presynaptic hyperekplexia KW - loss of function KW - structural disruption KW - glycine uptake Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-202574 ER - TY - JOUR A1 - Kitzenmaier, Alexandra A1 - Schaefer, Natascha A1 - Kasaragod, Vikram Babu A1 - Polster, Tilman A1 - Hantschmann, Ralph A1 - Schindelin, Hermann A1 - Villmann, Carmen T1 - The P429L loss of function mutation of the human glycine transporter 2 associated with hyperekplexia JF - European Journal of Neuroscience N2 - Glycine transporter 2 (GlyT2) mutations across the entire sequence have been shown to represent the presynaptic component of the neurological disease hyperekplexia. Dominant, recessive and compound heterozygous mutations have been identified, most of them leading to impaired glycine uptake. Here, we identified a novel loss of function mutation of the GlyT2 resulting from an amino acid exchange of proline 429 to leucine in a family with both parents being heterozygous carriers. A homozygous child suffered from severe neuromotor deficits. We characterised the GlyT2P429L variant at the molecular, cellular and protein level. Functionality was determined by glycine uptake assays. Homology modelling revealed that the mutation localises to α‐helix 5, presumably disrupting the integrity of this α‐helix. GlyT2P429L shows protein trafficking through various intracellular compartments to the cellular surface. However, the protein expression at the whole cell level was significantly reduced. Although present at the cellular surface, GlyT2P429L demonstrated a loss of protein function. Coexpression of the mutant with the wild‐type protein, reflecting the situation in the parents, did not affect transporter function, thus explaining their non‐symptomatic phenotype. Nevertheless, when the mutant was expressed in excess compared with the wild‐type protein, glycine uptake was significantly reduced. Thus, these data demonstrate that the proline residue at position 429 is structurally important for the correct formation of α‐helix 5. The failure in functionality of the mutated GlyT2 is most probably due to structural changes localised in close proximity to the sodium‐binding site of the transporter. KW - glycine transporter 2 KW - glyvine uptake KW - loss of function KW - presynaptic hyperekplexia KW - protein transport KW - structural disruption Y1 - 2019 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-206158 VL - 50 IS - 12 ER -